Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03229265 · ClinicalTrials.gov registry record · Phase 4
Pharmacokinetic Study of Tacrolimus and Mycophenolate Mofetil in Kidney Transplant Recipients With Hyperkalemia Receiving Patiromer
A Phase 4 study of Kidney Transplant and Hyperkalemia, sponsored by The Rogosin Institute.
- Completed
- Registry status
- Phase 4
- Development phase
- 8
- Enrollment target
- 1
- Study location
NCT03229265 is a Phase 4 study of Kidney Transplant and Hyperkalemia that has completed, run by The Rogosin Institute. The registered enrollment target is 8 participants, below the 1,898-participant average among 30 other Kidney Transplant trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03229265, a Phase 4 study of Kidney Transplant and Hyperkalemia, has completed, sponsored by The Rogosin Institute.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 8 participants
- Enrollment target
- 1
- Study location
Study Summary
Hyperkalemia (high potassium in blood) is a common condition found in kidney transplant patients. Risk factors include poor kidney function and exposure to various drugs. Regardless of the causes, current treatment options are limited. Previously, the only available potassium binder for lowering potassium in the blood is sodium polystyrene sulfonate, which has unknown drug interaction profile with transplant medications. Patiromer is a newly approved potassium binder indicated for the treatment of hyperkalemia. Kidney transplant patients with hyperkalemia may benefit from patiromer. However, the interaction of patiromer and transplant medications has not been studied. The goal of this study is to look into the drug interactions between patiromer and transplant medications.
Conditions Studied
Interventions
- DRUG Patiromer
Study Locations (1)
New York
- The Rogosin Institute - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2017-08-01 |
| Est. Completion | 2019-08-07 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03229265
The ClinicalTrials.gov registry entry for NCT03229265 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,898-participant average among 30 other Kidney Transplant trials with a reported enrollment target (100% lower). The listed sponsor is The Rogosin Institute, which has 21 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Kidney Transplant appearing as the primary indexed condition, and to 1 intervention - of which Patiromer is the first listed.
NCT03229265 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT03229265 about?
NCT03229265 is a clinical study titled "Pharmacokinetic Study of Tacrolimus and Mycophenolate Mofetil in Kidney Transplant Recipients With Hyperkalemia Receiving Patiromer". Hyperkalemia (high potassium in blood) is a common condition found in kidney transplant patients. Risk factors include poor kidney function and exposure to various drugs. Regardless of the causes, current treatment options are limited. Previously, the only available potassium binder for lowering pot...
What is the current status of trial NCT03229265?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 8 participants. The study started on 2017-08-01. Estimated completion is 2019-08-07.
What conditions does trial NCT03229265 study?
This clinical trial studies the following conditions: Kidney Transplant, Hyperkalemia.
What interventions are being tested in trial NCT03229265?
The interventions under investigation include: Patiromer (DRUG).
Who is sponsoring clinical trial NCT03229265?
This trial is sponsored by The Rogosin Institute, which has 21 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03229265 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Kidney Transplant
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Sparsentan in Posttransplant Immunoglobulin A Nephropathy or Focal Segmental Glomerulosclerosis
RECRUITING · Phase 4
-
Empagliflozin Treatment in Kidney Transplant Recipients
RECRUITING · Phase 4
-
Immunogenicity of HPV Vaccine in Transplant Recipients.
ACTIVE NOT RECRUITING · Phase 4
-
Dosing Strategies for de Novo Once-daily Extended Release Tacrolimus (LCPT) in Kidney Transplant Recipients
COMPLETED · Phase 4
-
Safety and Tolerability of Vertebral Bone Marrow-derived Mesenchymal Stem Cells (BM-MSC) in Real World Scenarios of Patients With Chronic Kidney Disease (CKD)
RECRUITING
-
Social Support Counseling Intervention for Kidney Transplant Candidates
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.